Combined antiretroviral therapy attenuates hepatic extracellular matrix remodeling in HIV patients assessed by novel protein fingerprint markers

AIDS

Volumn 28, Issue 14, 2014, Pages 2081-2090

  Leeming, Diana J ^a   Anadol, Evrim ^b   Schierwagen, Robert ^b   Karsdal, Morten A ^a   Byrjalsen, Inger ^a   Nielsen, Mette Juul ^a,c   Schwarzer Zander, Carolyn ^b   Boesecke, Christoph ^b   Bendtsen, Flemming ^d   Møller, Søren ^e   Strassburg, Christian P ^b   Spengler, Ulrich ^b   Krag, Aleksander ^c   Rockstroh, Jürgen ^b   Trebicka, Jonel K ^b  

^a NORDIC BIOSCIENCE A S   (Denmark)

^b UNIVERSITY OF BONN   (Germany)

^c ODENSE UNIVERSITY HOSPITAL   (Denmark)

^d German Center for Infection Research ^*  (Germany)

^e UNIVERSITY OF COPENHAGEN   (Denmark)

Author keywords

Combined antiretroviral therapy; Extracellular matrix; HIV viral load; HIV monoinfected; Protein fingerprint markers; Serological markers

Indexed keywords

ANTIRETROVIRUS AGENT; BIGLYCAN; BIOLOGICAL MARKER; COLLAGEN TYPE 3; COLLAGEN TYPE 4; ELASTIN; MATRIX METALLOPROTEINASE; PROTEIN P4NP 7S; SCLEROPROTEIN; UNCLASSIFIED DRUG; ANTIVIRUS AGENT;

ADULT; ARTICLE; CONTROLLED STUDY; DIAGNOSTIC ACCURACY; DIAGNOSTIC TEST ACCURACY STUDY; DIAGNOSTIC VALUE; DISEASE COURSE; ELASTOGRAPHY; ENZYME LINKED IMMUNOSORBENT ASSAY; EXTRACELLULAR MATRIX; FEMALE; HEPATITIS C; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LIVER FIBROSIS; MAJOR CLINICAL STUDY; MALE; MIXED INFECTION; NONHUMAN; PRIORITY JOURNAL; VIREMIA; VIRUS LOAD; BLOOD; CROSS-SECTIONAL STUDY; DRUG COMBINATION; FOLLOW UP; HIV INFECTIONS; LIVER CIRRHOSIS; LONGITUDINAL STUDY; METABOLISM; MIDDLE AGED; PATHOLOGY; PATHOPHYSIOLOGY; PEPTIDE MAPPING;

ADULT; ANTIVIRAL AGENTS; BIGLYCAN; BIOLOGICAL MARKERS; COINFECTION; COLLAGEN TYPE III; CROSS-SECTIONAL STUDIES; DISEASE PROGRESSION; DRUG THERAPY, COMBINATION; ELASTICITY IMAGING TECHNIQUES; ELASTIN; EXTRACELLULAR MATRIX; FEMALE; FOLLOW-UP STUDIES; HEPATITIS C; HIV INFECTIONS; HUMANS; LIVER CIRRHOSIS; LONGITUDINAL STUDIES; MALE; MIDDLE AGED; PEPTIDE MAPPING;

EID: 84906733667     PISSN: 02699370     EISSN: 14735571     Source Type: Journal    
DOI: 10.1097/QAD.0000000000000388     Document Type: Article

References (40)

1. Mocroft A, Ledergerber B, Katlama C, Kirk O, Reiss P, d' Arminio Monforte A, et al. Decline in the AIDS and death rates in the EuroSIDA study: an observational study. Lancet 2003; 362: 22-29.
2. Bica I, McGovern B, Dhar R, Stone D, McGowan K, Scheib R, et al. Increasing mortality due to end-stage liver disease in patients with human immunodeficiency virus infection. Clin Infect Dis 2001; 32: 492-497.
3. Merchante N, Girón-González JA, González-Serrano M, Torre-Cisneros J, García-García JA, Arizcorreta A, et al. Survival and prognostic factors of HIV-infected patients with HCV-related end-stage liver disease. AIDS 2006; 20: 49-57.
4. Macías J, Berenguer J, Japón MA, Girón JA, Rivero A, López-Cortés LF, et al. Fast fibrosis progression between repeated liver biopsies in patients coinfected with human immunodeficiency virus/hepatitis C virus. Hepatology 2009; 50: 1056-1063.
5. Tural C, Fuster D, Tor J, Ojanguren I, Sirera G, Ballesteros A, et al. Time on antiretroviral therapy is a protective factor for liver fibrosis in HIV and hepatitis C virus (HCV) co-infected patients. J Viral Hepat 2003; 10: 118-125.
6. Merchante N, Pérez-Camacho I, Mira JA, Rivero A, Macías J, Camacho A, et al. Prevalence and risk factors for abnormal liver stiffness in HIV-infected patients without viral hepatitis coinfection: role of didanosine. Antivir Ther (Lond) 2010; 15: 753-763.
7. Vermehren J, Vermehren A, Mueller A, Carlebach A, Lutz T, Gute P, et al. Assessment of liver fibrosis and associated risk factors in HIV-infected individuals using transient elastography and serum biomarkers. BMC Gastroenterol 2012; 12: 27.
8. DallaPiazza M, Amorosa VK, Localio R, Kostman JR, Lo Re V 3rd. Prevalence and risk factors for significant liver fibrosis among HIV-monoinfected patients. BMC Infect Dis 2010; 10: 116.
9. Tuyama AC, Hong F, Saiman Y, Wang C, Ozkok D, Mosoian A, et al. Human immunodeficiency virus (HIV)-1 infects human hepatic stellate cells and promotes collagen I and monocyte chemoattractant protein-1 expression: implications for the pathogenesis of HIV/hepatitis C virus-induced liver fibrosis. Hepatology 2010; 52: 612-622.
10. Baranova A, Lal P, Birerdinc A, Younossi ZM. Noninvasive markers for hepatic fibrosis. BMC Gastroenterol 2011; 11: 91.
11. Friedman SL. Mechanisms of hepatic fibrogenesis. Gastroenterology 2008; 134: 1655-1669.
12. Karsdal MA, Nielsen MJ, Sand JM, Henriksen K, Genovese F, Bay-Jensen A-C, et al. Extracellular matrix remodeling: the common denominator in connective tissue diseases. Possibilities for evaluation and current understanding of the matrix as more than a passive architecture, but a key player in tissue failure. Assay Drug Dev Technol 2013; 11: 70-92.
13. Veidal SS, Karsdal MA, Nawrocki A, Larsen MR, Dai Y, Zheng Q, et al. Assessment of proteolytic degradation of the basement membrane: a fragment of type IV collagen as a biochemical marker for liver fibrosis. Fibrogenesis Tissue Repair 2011; 4: 22.
14. Vassiliadis E, Larsen DV, Clausen RE, Veidal SS, Barascuk N, Larsen L, et al. Measurement of CO3-610, a potential liver biomarker derived from matrix metalloproteinase-9 degradation of collagen type iii, in a rat model of reversible carbontetrachloride-induced fibrosis. Biomark Insights 2011; 6: 49-58.
15. Leeming DJ, Nielsen MJ, Dai Y, Veidal SS, Vassiliadis E, Zhang C, et al. Enzyme-linked immunosorbent serum assay specific for the 7S domain of Collagen Type IV (P4NP 7S): A marker related to the extracellular matrix remodeling during liver fibrogenesis. Hepatol Res 2012; 42: 482-493.
16. Schierwagen R, Leeming DJ, Klein S, Granzow M, Nielsen MJ, Sauerbruch T, et al. Serum markers of the extracellular matrix remodeling reflect antifibrotic therapy in bile-duct ligated rats. Front Physiol 2013; 4: 195.
17. Leeming DJ, Karsdal MA, Byrjalsen I, Bendtsen F, Trebicka J, Nielsen MJ, et al. Novel serological neo-epitope markers of extracellular matrix proteins for the detection of portal hypertension. Aliment Pharmacol Ther 2013; 38: 1086-1096.
18. Kellner P, Anadol E, Hüneburg R, Hundt F, Bös D, Klein B, et al. The effect of hemodialysis on liver stiffness measurement: a single-center series. Eur J Gastroenterol Hepatol 2013; 25: 368-372.
19. Mouritzen U, Christgau S, Lehmann H-J, Tankó LB, Christiansen C. Cartilage turnover assessed with a newly developed assay measuring collagen type II degradation products: influence of age, sex, menopause, hormone replacement therapy, and body mass index. Ann Rheum Dis 2003; 62: 332-336.
20. Genovese F, Barascuk N, Larsen L, Larsen MR, Nawrocki A, Li Y, et al. Biglycan fragmentation in pathologies associated with extracellular matrix remodeling by matrix metalloproteinases. Fibrogenesis Tissue Repair 2013; 6: 9.
21. Skjøt-Arkil H, Clausen RE, Nguyen QHT, Wang Y, Zheng Q, Martinez FJ, et al. Measurement of MMP-9 and -12 degraded elastin (ELM) provides unique information on lung tissue degradation. BMC Pulm Med 2012; 12: 34.
22. Joshi D, O'Grady J, Dieterich D, Gazzard B, Agarwal K. Increasing burden of liver disease in patients with HIV infection. Lancet 2011; 377: 1198-1209.
23. Glässner A, Eisenhardt M, Kokordelis P, Krämer B, Wolter F, Nischalke HD, et al. Impaired CD4R T cell stimulation of NK cell antifibrotic activity may contribute to accelerated liver fibrosis progression in HIV/HCV patients. J Hepatol 2013; 59: 427-433.
24. Redd AD, Wendel SK, Grabowski MK, Ocama P, Kiggundu V, Bbosa F, et al. Liver stiffness is associated with monocyte activation in HIV-infected Ugandans without viral hepatitis. AIDS Res Hum Retroviruses 2013; 29: 1026-1030.
25. Núñez M. Clinical syndromes and consequences of antiretroviral-related hepatotoxicity. Hepatology 2010; 52: 1143-1155.
26. Qurishi N, Kreuzberg C, Lüchters G, Effenberger W, Kupfer B, Sauerbruch T, et al. Effect of antiretroviral therapy on liverrelated mortality in patients with HIV and hepatitis C virus coinfection. Lancet 2003; 362: 1708-1713.
27. Vogel M, Rockstroh JK. Hepatotoxicity and liver disease in the context of HIV therapy. Curr Opin HIV AIDS 2007; 2: 306-313.
28. Blanco F, Barreiro P, Ryan P, Vispo E, Martín-Carbonero L, Tuma P, et al. Risk factors for advanced liver fibrosis in HIVinfected individuals: role of antiretroviral drugs and insulin resistance. J Viral Hepat 2011; 18: 11-16.
29. Kovari H, Ledergerber B, Battegay M, Rauch A, Hirschel B, Foguena AK, et al. Incidence and risk factors for chronic elevation of alanine aminotransferase levels in HIV-infected persons without hepatitis b or c virus co-infection. Clin Infect Dis 2010; 50: 502-511.
30. Loko MA, Bani-Sadr F, Winnock M, Lacombe K, Carrieri P, Neau D, et al. Impact of HAART exposure and associated lipodystrophy on advanced liver fibrosis in HIV/HCV-coinfected patients. J Viral Hepat 2011; 18: e307-e314.
31. Han SH, Kim SU, Kim CO, Jeong SJ, Park JY, Choi JY, et al. Abnormal liver stiffness assessed using transient elastography (Fibroscan() in HIV-infected patients without HBV/HCV coinfection receiving combined antiretroviral treatment. PLoS One 2013; 8: e52720.
32. Stabinski L, Reynolds SJ, Ocama P, Laeyendecker O, Ndyanabo A, Kiggundu V, et al. High prevalence of liver fibrosis associated with HIV infection: a study in rural Rakai, Uganda. Antivir Ther (Lond) 2011; 16: 405-411.
33. Mendeni M, Focà E, Gotti D, Ladisa N, Angarano G, Albini L, et al. Evaluation of liver fibrosis: concordance analysis between noninvasive scores (APRI and FIB-4) evolution and predictors in a cohort of HIV-infected patients without hepatitis C and B infection. Clin Infect Dis 2011; 52: 1164-1173.
34. Shaheen AAM, Wan AF, Myers RP. FibroTest and FibroScan for the prediction of hepatitis C-related fibrosis: a systematic review of diagnostic test accuracy. Am J Gastroenterol 2007; 102: 2589-2600.
35. Cacoub P, Carrat F, Bédossa P, Lambert J, Pénaranda G, Perronne C, et al. Comparison of noninvasive liver fibrosis biomarkers in HIV/HCV co-infected patients: the fibrovic study: ANRS HC02. J Hepatol 2008; 48: 765-773.
36. Charpentier C, Champenois K, Gervais A, Landman R, Joly V, Le Gac S, et al. Predictive value of liver enzymes and inflammatory biomarkers for the severity of liver fibrosis stage in HIV/HCV co-infected patients. PLoS One 2013; 8: e59205.
37. Schaefer L, Babelova A, Kiss E, Hausser H-J, Baliova M, Krzyzankova M, et al. The matrix component biglycan is proinflammatory and signals through Toll-like receptors 4 and 2 in macrophages. J Clin Invest 2005; 115: 2223-2233.
38. Suárez-Zarracina T, Valle-Garay E, Collazos J, Montes AH, Cárcaba V, Carton JA, et al. Didanosine (ddI) associates with increased liver fibrosis in adult HIV-HCV coinfected patients. J Viral Hepat 2012; 19: 685-693.
39. Kennedy A, Hennessy M, Bergin C, Mulcahy F, Hopkins S, Spiers JP. Ribavirin and interferon alter MMP-9 abundance in vitro and in HIV-HCV-coinfected patients. Antivir Ther (Lond) 2011; 16: 1237-1247.
40. Mastroianni CM, Liuzzi GM, D'Ettorre G, Lichtner M, Forcina G, Di Campli NF, et al. Matrix metalloproteinase-9 and tissue inhibitors of matrix metalloproteinase-1 in plasma of patients co-infected with HCV and HIV. HIV Clin Trials 2002; 3: 310-315.